Thus, for early-stage patients with a low immune score, the OS of melanoma patients with tumors of high SOX10 (Wald test, p = 0.0012) or MLANA (Wald test, p = 0.0051) was worse than that of those with low levels of SOX10 or MLANA. The gene discussed is MLANA; the disease is melanoma.